

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 17597

Title: Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients

Reviewer's code: 01567591

Reviewer's country: Canada

Science editor: Ya-Juan Ma

Date sent for review: 2015-03-16 14:58

Date reviewed: 2015-04-27 21:05

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients. Comments to authors: This review gives a summary of the data from clinical trial on DAAs combinations for the management of liver transplant candidates and recipients. Although more clinical trials will be required to identify the best suitable treatment for these difficult to treat patients, this review give a clear update on the present situation in this rapidly evolving field. I support its publication in WJG. Minor comments: -The authors should describe in more detail what is the Child-Pugh score classification (Child Class A, B and C). A=5-6, B... -Others recent reviews addressing the same subject are not cited (Ex. Dall'Agata et al., WJG 2014). -Page 9 : No dose adjustment dose of sofosbuvir ... -Table 2: There is no mention of SVR in the table even though SVR is in the legend.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 17597

Title: Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients

Reviewer's code: 01560031

Reviewer's country: Japan

Science editor: Ya-Juan Ma

Date sent for review: 2015-03-16 14:58

Date reviewed: 2015-04-30 15:12

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input checked="" type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The paper is interesting, however some problems remain to be clarified. Major points: 1. Concerning the triple combination of pegIFN, RBV and boceprevir or telaprevir, the authors should cite another reference where better SVR was observed in naive patients, relapsers and null responders. Example; Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014 Jun; 59(6): 2083-91. 2. The authors should describe regarding SVR rates of the triple combination of pegIFN, RBV and simeprevir. Example; Hayashi N, Seto C, Kato M, Komada Y, Goto S. Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-na?ve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol. 2014 Jan; 49(1): 138-47. 3. Regarding the reference [16], the author should describe the genotype of LT candidate in the first open label phase study. Similarly, the authors should describe the genotype of patients treated with DAAs, cited from the other references, no.25, 29, 39, 40. 4. Simeprevir is a low genetic barrier drug, although the authors described "Safe regimens with high potency and high genetic barrier should be preferred to achieve



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<http://www.wjgnet.com>

rapid inhibition of HCV replication and eliminate the selection risk of resistant-associated viral strains". How do the authors think about genetic barrier of simeprevir. Miner points: 1. Page 15, Reference 6, you mistook the publication year of the journal "Journal of Viral Hepatitis", 200 → 2004.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 17597

Title: Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients

Reviewer's code: 02528284

Reviewer's country: Greece

Science editor: Ya-Juan Ma

Date sent for review: 2015-03-16 14:58

Date reviewed: 2015-03-20 16:40

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

A well written manuscript which summarizes the literature for this very interesting subject concerning interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients.